CyberOncology Network Project

Multicenter cohort study on real-world data collection in cancer treatment. - CONNECT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044646

Enrollment

5000

Registered

2021-06-24

Start date

2025-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with solid tumors who are eligible for cancer chemotherapy. Cases for which consent was obtained to participate in this study.

Exclusion criteria

Exclusion criteria: Cases that the researcher deems inappropriate for participating in this study.

Design outcomes

Primary

Measure	Time frame
Own data 1) Statistical data (A) Cancer type (OncoTree, ICD-O-3): Number of patients (new / total) / diagnosis date (B) Chemotherapy (number / content): Patient (new / total), drug, regimen (C) Basic patient information: age, gender, PS, cStage (TNM), race (D) Treatment method (number / content): Chemotherapy / surgery / radiation 2) Treatment results (A) Progression-free survival (postoperative chemotherapy is recurrence-free survival): Cancer type, line, regimen (B) Successful treatment period: Cancer type, line, regimen (C) Overall survival: cancer type, line, regimen (D) Response rate: Cancer type, line, regimen 3) Adverse events (A) Cancer type / line / regimen (B) SAE report	—

Measure

Time frame

Own data 1) Statistical data (A) Cancer type (OncoTree, ICD-O-3): Number of patients (new / total) / diagnosis date (B) Chemotherapy (number / content): Patient (new / total), drug, regimen (C) Basic patient information: age, gender, PS, cStage (TNM), race (D) Treatment method (number / content): Chemotherapy / surgery / radiation 2) Treatment results (A) Progression-free survival (postoperative chemotherapy is recurrence-free survival): Cancer type, line, regimen (B) Successful treatment period: Cancer type, line, regimen (C) Overall survival: cancer type, line, regimen (D) Response rate: Cancer type, line, regimen 3) Adverse events (A) Cancer type / line / regimen (B) SAE report

—

Secondary

Measure	Time frame
Multicenter integrated data 1) Statistical data (A) Cancer type (OncoTree, ICD-O-3): Number of patients (new / total) / diagnosis date (B) Chemotherapy (number / content): Patient (new / total), drug, regimen (C) Basic patient information: age, gender, PS, cStage (TNM), race (D) Treatment method (number / content): Chemotherapy / surgery / radiation 2) Treatment results (A) Progression-free survival (postoperative chemotherapy is recurrence-free survival): Cancer type, line, regimen (B) Successful treatment period: Cancer type, line, regimen (C) Overall survival: cancer type, line, regimen (D) Response rate: Cancer type, line, regimen 3) Adverse events (A) Cancer type / line / regimen (B) SAE report	—

Measure

Time frame

Multicenter integrated data 1) Statistical data (A) Cancer type (OncoTree, ICD-O-3): Number of patients (new / total) / diagnosis date (B) Chemotherapy (number / content): Patient (new / total), drug, regimen (C) Basic patient information: age, gender, PS, cStage (TNM), race (D) Treatment method (number / content): Chemotherapy / surgery / radiation 2) Treatment results (A) Progression-free survival (postoperative chemotherapy is recurrence-free survival): Cancer type, line, regimen (B) Successful treatment period: Cancer type, line, regimen (C) Overall survival: cancer type, line, regimen (D) Response rate: Cancer type, line, regimen 3) Adverse events (A) Cancer type / line / regimen (B) SAE report

—

Countries

Japan

Contacts

Public ContactShigemi Matsumoto

Kyoto University Department of Real world data R& D, Graduate School of Medicine

motocame@kuhp.kyoto-u.ac.jp075-751-4349

Outcome results